Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., have announced promising results from the RELIEVE UCCD phase 2b study, which met its primary endpoints in patients…
Gilead Sciences, Inc announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with extensive-stage small cell lung cancer…
Gilead Sciences, Inc and Terray Therapeutics, Inc. have entered into a strategic collaboration aimed at discovering and developing novel small molecule therapies across multiple therapeutic targets. This partnership leverages Terray’s…
Merck known as MSD outside of the United States and Canada, has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab…
GSK plc has announced that ViiV Healthcare, the global HIV-focused company majority owned by GSK with Pfizer and Shionogi as shareholders, received a positive opinion from the Committee for Medicinal…
Grifols, a global healthcare leader and prominent manufacturer of plasma-derived medicines, has achieved the distinction of being ranked the number one biotechnology company in the S&P Dow Jones Sustainability Indices…
UCB has announced results from the ORCHESTRA proof-of-concept study evaluating minzasolmin, an investigational oral small molecule developed in collaboration with Novartis to inhibit alpha-synuclein misfolding in early-stage Parkinson’s disease. Unfortunately,…
Jazz Pharmaceuticals plc has announced a pivotal leadership transition, as Bruce Cozadd, the company’s Co-Founder, Chairperson, and Chief Executive Officer (CEO), plans to retire from his role upon the appointment…
We, the member countries of the Group of Friends of the WHO Academy, reaffirm our steadfast commitment to supporting the WHO Academy as a vital mechanism for enhancing the skills…
Lupin Digital Health, a wholly owned subsidiary of the global pharmaceutical leader Lupin Limited, has announced a strategic collaboration with Medicover Hospitals to enhance cardiac care for patients in India.…
Lupin Limited, a leading global pharmaceutical company, has announced the acquisition of three key anti-diabetes trademarks—GIBTULIO®, GIBTULIO MET®, and AJADUO®—from Boehringer Ingelheim International GmbH. This strategic move is aimed at…
Neurocrine Biosciences,has announced that the U.S. Food and Drug Administration (FDA) has approved CRENESSITY™ (crinecerfont) capsules and oral solution for use as an adjunctive treatment to glucocorticoid replacement in adults…